Abstract
PD-1/PD-L1 interaction affects various immune cells, including macrophage and dendritic cells, which play crucial roles in anti-cancer immunity. Early alteration of inflammatory cytokines, such as IL-6, TNF-α, or CRP, which is a surrogate marker for IL-6, following anti-PD-1 antibody administration may represent activation of those cells and be related to the efficacy and safety of anti-PD-1 antibody treatment; however, these remain unexplored thus far.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
